Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients

Lucien Roulet, Victoria Rollason, Jules Desmeules, Valérie Piguet, Lucien Roulet, Victoria Rollason, Jules Desmeules, Valérie Piguet

Abstract

We conducted a narrative review of the literature to compare the pharmacological, efficacy and safety profiles of tapentadol and tramadol, and to assess the clinical interest of tapentadol in adult patients. Tapentadol and tramadol share a mixed mechanism of action, including both mu-agonist and monoaminergic properties. Tapentadol is approximately two to three times more potent than tramadol and two to three times less potent than morphine. It has no identified analgesically active metabolite and is not significantly metabolised by cytochrome P450 enzymes, thus overcoming some limitations of tramadol, including the potential for pharmacokinetic drug-drug interactions and interindividual variability due to genetic polymorphisms of cytochrome P450 enzymes. The toxicity profiles of tramadol and tapentadol are similar; however tapentadol is likely to result in less exposure to serotoninergic adverse effects (nausea, vomiting, hypoglycaemia) but cause more opioid adverse effects (constipation, respiratory depression, abuse) than tramadol. The safety of tapentadol in real-world conditions remains poorly documented, particularly in at-risk patient subgroups and also in the ability to assess the risk associated with its residual serotonergic activity (serotonin syndrome, seizures). Because of an earlier market introduction, more real-world safety data are available for tramadol, including data from at-risk patient subgroups. The level of evidence on the efficacy of both tramadol and tapentadol for the treatment of chronic pain is globally low. The trials published to date show overall that tapentadol does not provide a clinically significant analgesic improvement compared to existing treatments, for which the safety profile is much better known. In conclusion, tapentadol is not a first-line opioid but represents an additional analgesic in the therapeutic choices, which some patients may benefit from after careful examination of their clinical situation, co-morbidities and co-medications.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Conditions of prescription and delivery of tramadol (a) and tapentadol (b) in Europe (situation in 2015). Reproduced with permission from Palmaro et al. [127]

References

    1. MacKenzie M, Zed PJ, Ensom MHH. Opioid pharmacokinetics-pharmacodynamics: clinical implications in acute pain management in trauma. Ann Pharmacother. 2016;50(3):209–218. doi: 10.1177/1060028015625659.
    1. Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7:CD012592.
    1. Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018;320(23):2448–2460. doi: 10.1001/jama.2018.18472.
    1. Sommer C, Klose P, Welsch P, Petzke F, Häuser W. Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Eur J Pain. 2020;24(1):3–18. doi: 10.1002/ejp.1494.
    1. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996;383(6603):819–823. doi: 10.1038/383819a0.
    1. Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs. 2008;68(18):2611–2632. doi: 10.2165/0003495-200868180-00007.
    1. Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies H-H, Englberger W, et al. (–)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323(1):265–276. doi: 10.1124/jpet.107.126052.
    1. Raffa RB, Haidery M, Huang H-M, Kalladeen K, Lockstein DE, Ono H, et al. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014;39(6):577–583. doi: 10.1111/jcpt.12196.
    1. Barbosa J, Faria J, Queirós O, Moreira R, Carvalho F, Dinis-Oliveira RJ. Comparative metabolism of tramadol and tapentadol: a toxicological perspective. Drug Metab Rev. 2016;48(4):577–592. doi: 10.1080/03602532.2016.1229788.
    1. Faria J, Barbosa J, Moreira R, Queirós O, Carvalho F, Dinis-Oliveira RJ. Comparative pharmacology and toxicology of tramadol and tapentadol. Eur J Pain. 2018;22(5):827–844. doi: 10.1002/ejp.1196.
    1. Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012;13(10):1437–1449. doi: 10.1517/14656566.2012.696097.
    1. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an « atypical » opioid analgesic. J Pharmacol Exp Ther. 1992;260(1):275–285.
    1. Desmeules JA, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol. 1996;41(1):7–12. doi: 10.1111/j.1365-2125.1996.tb00152.x.
    1. Raffa RB, Elling C, Tzschentke TM. Does « strong analgesic » equal « strong opioid »? tapentadol and the concept of « µ-Load ». Adv Ther. 2018;35(10):1471–1484. doi: 10.1007/s12325-018-0778-x.
    1. Malonne H, Sonet B, Streel B, Lebrun S, De Niet S, Sereno A, et al. Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. Br J Clin Pharmacol. 2004;57(3):270–278. doi: 10.1046/j.1365-2125.2003.02013.x.
    1. Cnota PJ, Nowak H, Tagarro I, Erb K, Schürer M, Schulz H-U, et al. Tramadol SR formulations : pharmacokinetic comparison of a multiple-units dose (Capsule) versus a single-unit dose (Tablet) Clin Drug Investig. 2005;25(7):435–443. doi: 10.2165/00044011-200525070-00002.
    1. Fliegert F, Kurth B, Göhler K. The effects of tramadol on static and dynamic pupillometry in healthy subjects–the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol. 2005;61(4):257–266. doi: 10.1007/s00228-005-0920-y.
    1. Göhler K, Brett M, Smit JW, Rengelshausen J, Terlinden R. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013;51(4):338–348. doi: 10.5414/CP201722.
    1. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923. doi: 10.2165/00003088-200443130-00004.
    1. Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17(Suppl 11):S276–287.
    1. Terlinden R, Kogel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol. 2010;32(1):31–38. doi: 10.1358/mf.2010.32.1.1434165.
    1. Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2007;32(3):163–169. doi: 10.1007/BF03190478.
    1. Mercadante S, Porzio G, Aielli F, Adile C, Verna L, Ficorella C, et al. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013;29(6):661–666. doi: 10.1185/03007995.2013.791617.
    1. Gálvez R, Schäfer M, Hans G, Falke D, Steigerwald I. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Adv Ther. 2013;30(3):229–259. doi: 10.1007/s12325-013-0015-6.
    1. Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol. 1994;5(2):141–146. doi: 10.1093/oxfordjournals.annonc.a058765.
    1. Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation Expert panel on evidence review and guidelines for opioid rotation. establishing « best practices » for opioid rotation: conclusions of an expert panel. J Pain Symptom Manag. 2009;38(3):418–425. doi: 10.1016/j.jpainsymman.2009.06.002.
    1. Scott LJ, Perry CM. Tramadol: a review of its use in perioperative pain. Drugs. 2000;60(1):139–176. doi: 10.2165/00003495-200060010-00008.
    1. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs. 1993;46(2):313–340. doi: 10.2165/00003495-199346020-00008.
    1. Owsiany MT, Hawley CE, Triantafylidis LK, Paik JM. Opioid management in older adults with chronic kidney disease: a review. Am J Med. 2019;132(12):1386–1393. doi: 10.1016/j.amjmed.2019.06.014.
    1. Launay-Vacher V, Karie S, Fau J-B, Izzedine H, Deray G. Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain. 2005;6(3):137–148. doi: 10.1016/j.jpain.2004.11.009.
    1. Bourquin V, Petignat P-A, Besson M, Piguet V. Analgesia and renal insufficiency. Rev Med Suisse. 2008;4(175):2218–2220.
    1. Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs. 2012;72(12):1645–1669. doi: 10.2165/11635500-000000000-00000.
    1. Skinner-Robertson S, Fradette C, Bouchard S, Mouksassi M-S, Varin F. Pharmacokinetics of tramadol and O-desmethyltramadol enantiomers following administration of extended-release tablets to elderly and young subjects. Drugs Aging. 2015;32(12):1029–1043. doi: 10.1007/s40266-015-0315-4.
    1. Freo U, Furnari M, Ambrosio F, Navalesi P. Efficacy and tolerability of tapentadol for the treatment of chronic low back pain in elderly patients. Aging Clin Exp Res. 2021;33(4):973–82.
    1. Schwittay A, Sohns M, Heckes B, Elling C. Tapentadol prolonged release for severe chronic osteoarthritis pain in the elderly—a Subgroup Analysis of Routine Clinical Practice Data. Pain Res Manag. 2020;2020:5759265. doi: 10.1155/2020/5759265.
    1. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229–243. doi: 10.1517/14622416.3.2.229.
    1. Dean L. Tramadol Therapy and CYP2D6 Genotype. In: Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, et al., éditeurs. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012 [cited 22 dec 2020]. . Accessed 22 Dec 2020
    1. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–673. doi: 10.1038/clpt.2011.34.
    1. Veal FC, Peterson GM. Pain in the frail or elderly patient: does tapentadol have a role? Drugs Aging. 2015;32(6):419–426. doi: 10.1007/s40266-015-0268-7.
    1. Qaseem A, Wilt TJ, McLean RM, Forciea MA, Clinical Guidelines Committee of the American College of Physicians Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514–530. doi: 10.7326/M16-2367.
    1. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131–157. doi: 10.1016/j.jpain.2015.12.008.
    1. Marcou TA, Marque S, Mazoit J-X, Benhamou D. The median effective dose of tramadol and morphine for postoperative patients: a study of interactions. Anesth Analg. 2005;100(2):469–474. doi: 10.1213/01.ANE.0000142121.24052.25.
    1. Wang X, Narayan SW, Penm J, Patanwala AE. Efficacy and Safety of Tapentadol Immediate Release for Acute Pain: A Systematic Review and Meta-analysis. Clin J Pain. 2020;36(5):399–409. doi: 10.1097/AJP.0000000000000809.
    1. Malonne H, Coffiner M, Sonet B, Sereno A, Vanderbist F. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004;26(11):1774–1782. doi: 10.1016/j.clinthera.2004.11.005.
    1. Fishman RL, Kistler CJ, Ellerbusch MT, Aparicio RT, Swami SS, Shirley ME, et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid OAD) J Opioid Manag. 2007;3(5):273–280. doi: 10.5055/jom.2007.0015.
    1. Burch F, Fishman R, Messina N, Corser B, Radulescu F, Sarbu A, et al. A comparison of the analgesic efficacy of Tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. J Pain Symptom Manage. 2007;34(3):328–338. doi: 10.1016/j.jpainsymman.2006.11.017.
    1. Toupin April K, Bisaillon J, Welch V, Maxwell LJ, Jüni P, Rutjes AW, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2019;5:CD005522.
    1. Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30(8):489–505. doi: 10.2165/11533440-000000000-00000.
    1. Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11(11):1787–1804. doi: 10.1517/14656566.2010.497720.
    1. Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Phys. 2013;16(1):27–40. doi: 10.36076/ppj.2013/16/27.
    1. Santos J, Alarcão J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015;5:CD009923.
    1. Oliveira CB, Maher CG, Pinto RZ, Traeger AC, Lin C-WC, Chenot J-F, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27(11):2791–2803. doi: 10.1007/s00586-018-5673-2.
    1. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220–233. doi: 10.1002/art.41142.
    1. Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017;5:CD012508.
    1. Rodriguez RF, Bravo LE, Castro F, Montoya O, Castillo JM, Castillo MP, et al. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med. 2007;10(1):56–60. doi: 10.1089/jpm.2006.0117.
    1. Leppert W, Majkowicz M. The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain. Int J Clin Pract. 2010;64(12):1681–1687. doi: 10.1111/j.1742-1241.2010.02422.x.
    1. Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol. 2016;34(5):436–442. doi: 10.1200/JCO.2015.61.0733.
    1. Carmona-Bayonas A, Jiménez Fonseca P, Virizuela EJ. Tapentadol for cancer pain management: a narrative review. Pain Pract. 2017;17(8):1075–1088. doi: 10.1111/papr.12556.
    1. Imanaka K, Tominaga Y, Etropolski M, van Hove I, Ohsaka M, Wanibe M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin. 2013;29(10):1399–1409. doi: 10.1185/03007995.2013.831816.
    1. Imanaka K, Tominaga Y, Etropolski M, Ohashi H, Hirose K, Matsumura T. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clin Drug Investig. 2014;34(7):501–511. doi: 10.1007/s40261-014-0204-3.
    1. Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Phys. 2014;17(4):329–343. doi: 10.36076/ppj.2014/17/329.
    1. Wiffen PJ, Derry S, Naessens K, Bell RF. Oral tapentadol for cancer pain. Cochrane Database Syst Rev. 2015;9:CD011460.
    1. Alam U, Sloan G, Tesfaye S. Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs. Drugs. 2020;80(4):363–384. doi: 10.1007/s40265-020-01259-2.
    1. Desai B, Freeman E, Huang E, Hung A, Knapp E, Breunig IM, et al. Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy. Expert Rev Clin Pharmacol. 2014;7(2):203–209. doi: 10.1586/17512433.2014.889562.
    1. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50(6):1842–1846. doi: 10.1212/WNL.50.6.1842.
    1. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003;104(1–2):323–331. doi: 10.1016/S0304-3959(03)00020-4.
    1. Sindrup SH, Konder R, Lehmann R, Meier T, Winkel M, Ashworth J, et al. Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy. Eur J Pain. 2012;16(6):849–859. doi: 10.1002/j.1532-2149.2011.00069.x.
    1. Norrbrink C, Lundeberg T. Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial. Clin J Pain. 2009;25(3):177–184. doi: 10.1097/AJP.0b013e31818a744d.
    1. Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD003726.
    1. Mu A, Weinberg E, Moulin DE, Clarke H. Pharmacologic management of chronic neuropathic pain: review of the Canadian Pain Society consensus statement. Can Fam Physician. 2017;63(11):844–852.
    1. Bates D, Schultheis BC, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019;20(Suppl 1):S2–12. doi: 10.1093/pm/pnz075.
    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi: 10.1016/S1474-4422(14)70251-0.
    1. Finnerup NB, Attal N. Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy–authors’ reply. Lancet Neurol. 2015;14(7):685–686. doi: 10.1016/S1474-4422(15)00060-5.
    1. Rosenthal NR, Silverfield JC, Wu S-C, Jordan D, Kamin M, CAPSS-105 Study Group Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population. J Am Geriatr Soc. 2004;52(3):374–380. doi: 10.1111/j.1532-5415.2004.52108.x.
    1. Vorsanger G, Xiang J, Jordan D, Farrell J. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clin Ther. 2007;29(Suppl):2520–2535. doi: 10.1016/j.clinthera.2007.12.009.
    1. Biondi DM, Xiang J, Etropolski M, Moskovitz B. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. J Opioid Manag. 2015;11(5):393–403. doi: 10.5055/jom.2015.0289.
    1. Lange B, Sohns M, Tempero J, Elling C. Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials. Curr Med Res Opin. 2018;34(12):2113–2123. doi: 10.1080/03007995.2018.1520085.
    1. Kern K-U, Sohns M, Heckes B, Elling C. Tapentadol prolonged release for severe chronic osteoarthritis pain in the elderly: improvements in daily functioning and quality of life. Pain Manag. 2020;10(2):85–95. doi: 10.2217/pmt-2019-0041.
    1. van Ojik AL, Jansen PAF, Brouwers JRBJ, van Roon EN. Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids. Drugs Aging. 2012;29(8):615–625. doi: 10.1007/BF03262278.
    1. Pergolizzi JV, LeQuang JA, Taylor R, Ossipov MH, Colucci D, Raffa RB. Designing safer analgesics: a focus on μ-opioid receptor pathways. Expert Opin Drug Discov. 2018;13(10):965–972. doi: 10.1080/17460441.2018.1511539.
    1. Olson KM, Duron DI, Womer D, Fell R, Streicher JM. Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids. PLoS ONE. 2019;14(6):e0217371. doi: 10.1371/journal.pone.0217371.
    1. Pasternak GW, Pan Y-X. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257–1317. doi: 10.1124/pr.112.007138.
    1. Faria J, Barbosa J, Leal S, Afonso LP, Lobo J, Moreira R, et al. Effective analgesic doses of tramadol or tapentadol induce brain, lung and heart toxicity in Wistar rats. Toxicology. 2017;385:38–47. doi: 10.1016/j.tox.2017.05.003.
    1. Barbosa J, Faria J, Leal S, Afonso LP, Lobo J, Queirós O, et al. Acute administration of tramadol and tapentadol at effective analgesic and maximum tolerated doses causes hepato- and nephrotoxic effects in Wistar rats. Toxicology. 2017;389:118–129. doi: 10.1016/j.tox.2017.07.001.
    1. Cossmann M, Kohnen C, Langford R, McCartney C. Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance. Drugs. 1997;53(Suppl 2):50–62. doi: 10.2165/00003495-199700532-00010.
    1. Stollenwerk A, Sohns M, Heisig F, Elling C, von Zabern D. Review of post-marketing safety data on tapentadol, a centrally acting analgesic. Adv Ther. 2018;35(1):12–30. doi: 10.1007/s12325-017-0654-0.
    1. DeLemos B, Richards HM, Vandenbossche J, Ariyawansa J, Natarajan J, Alexander B, et al. Safety, tolerability, and pharmacokinetics of therapeutic and supratherapeutic doses of tramadol hydrochloride in healthy adults: a Randomized, Double-Blind, Placebo-Controlled Multiple-Ascending-Dose Study. Clin Pharmacol Drug Dev. 2017;6(6):592–603. doi: 10.1002/cpdd.378.
    1. Petrone D, Kamin M, Olson W. Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/or vomiting: a double-blind randomized trial. J Clin Pharm Ther. 1999;24(2):115–123. doi: 10.1046/j.1365-2710.1999.00203.x.
    1. Montastruc F, Benevent J, Chebane L, Rousseau V, Durrieu G, Sommet A, et al. Vomiting and constipation associated with tramadol and codeine: a comparative study in VigiBase®. Eur J Clin Pharmacol. 2018;74(12):1673–1674. doi: 10.1007/s00228-018-2536-z.
    1. Moulis F, Rousseau V, Abadie D, Masmoudi K, Micallef J, Vigier C, et al. Serious adverse drug reactions with tramadol reported to the French pharmacovigilance database between 2011 and 2015. Therapie. 2017;72(6):615–624. doi: 10.1016/j.therap.2017.03.004.
    1. Wilder-Smith CH, Bettiga A. The analgesic tramadol has minimal effect on gastrointestinal motor function. Br J Clin Pharmacol. 1997;43(1):71–75. doi: 10.1111/j.1365-2125.1997.tb00140.x.
    1. Hartrick CT, Rozek RJ. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs. 2011;25(5):359–370. doi: 10.2165/11589080-000000000-00000.
    1. Nieuwenhuijs D, Bruce J, Drummond GB, Warren PM, Dahan A. Influence of oral tramadol on the dynamic ventilatory response to carbon dioxide in healthy volunteers. Br J Anaesth. 2001;87(6):860–865. doi: 10.1093/bja/87.6.860.
    1. van der Schrier R, Jonkman K, van Velzen M, Olofsen E, Drewes AM, Dahan A, et al. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers. Br J Anaesth. 2017;119(6):1169–1177. doi: 10.1093/bja/aex295.
    1. Tsutaoka BT, Ho RY, Fung SM, Kearney TE. Comparative toxicity of tapentadol and tramadol utilizing data reported to the national poison data system. Ann Pharmacother. 2015;49(12):1311–1316. doi: 10.1177/1060028015604631.
    1. Navarroza RV, Zamora LD, Navarra SV. Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease. Int J Rheum Dis. 2019;22(10):1933–1936. doi: 10.1111/1756-185X.13683.
    1. Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2018;175(3):532–543. doi: 10.1111/bph.14105.
    1. Gressler LE, Hammond DA, Painter JT. Serotonin syndrome in tapentadol literature: systematic review of original research. J Pain Palliat Care Pharmacother. 2017;31(3–4):228–236. doi: 10.1080/15360288.2017.1416440.
    1. Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Br J Anaesth. 2020;124(1):44–62. doi: 10.1016/j.bja.2019.08.010.
    1. Medicines and Healthcare products Regulatory Agency (UK). Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines. [Internet]. 2019.
    1. Chrétien B, Dolladille C, Hamel-Sénécal L, Sassier M, Faillie JL, Miremont-Salamé G, et al. Comparative study of hypoglycaemia induced by opioids. Is it a class effect? Expert Opin Drug Saf. 2019;18(10):987–992. doi: 10.1080/14740338.2019.1646246.
    1. Juba KM, van Manen RP, Fellows SE. A review of the food and drug administration adverse event reporting system for tramadol-related hypoglycemia. Ann Pharmacother. 2020;54(3):247–253. doi: 10.1177/1060028019885643.
    1. Brož J, Brožová K, Malinovská J. Letter to the editor: hypoglycemia and treatment with opioids. Expert Opin Drug Saf. 2019;18(12):1263. doi: 10.1080/14740338.2019.1673363.
    1. Massarella J, Ariyawansa J, Natarajan J, Francke S, Murtaugh T, DeLemos B, et al. Tramadol hydrochloride at steady state lacks clinically relevant QTc interval increases in healthy adults. Clin Pharmacol Drug Dev. 2019;8(1):95–106. doi: 10.1002/cpdd.473.
    1. Biondi DM, Xiang J, Etropolski M, Moskovitz B. Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. Clin Drug Investig. 2014;34(8):565–576. doi: 10.1007/s40261-014-0209-y.
    1. Sanders P. Tapentadol analgesic interaction with clonidine. Pain Med. 2013;14(6):943–944. doi: 10.1111/pme.12134.
    1. Oh C, Rengelshausen J, Mangold B, Etropolski M, Rauschkolb C, Wang SS, et al. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. Int J Clin Pharmacol Ther. 2010;48(10):678–687. doi: 10.5414/CPP48678.
    1. Dunn KE, Tompkins DA, Bigelow GE, Strain EC. Efficacy of tramadol extended-release for opioid withdrawal: a randomized clinical trial. JAMA Psychiat. 2017;74(9):885–893. doi: 10.1001/jamapsychiatry.2017.1838.
    1. Thiels CA, Habermann EB, Hooten WM, Jeffery MM. Chronic use of tramadol after acute pain episode: cohort study. BMJ. 2019;365:l1849. doi: 10.1136/bmj.l1849.
    1. Dart RC, Bartelson BB, Adams EH. Nonmedical use of tapentadol immediate release by college students. Clin J Pain. 2014;30(8):685–692. doi: 10.1097/AJP.0000000000000001.
    1. Khaja M, Lominadze G, Millerman K. Cardiac arrest following drug abuse with intravenous tapentadol: case report and literature review. Am J Case Rep. 2017;18:817–821. doi: 10.12659/AJCR.904695.
    1. Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med. 2015;16(1):119–130. doi: 10.1111/pme.12524.
    1. Vosburg SK, Severtson SG, Dart RC, Cicero TJ, Kurtz SP, Parrino MW, et al. Assessment of tapentadol API abuse liability with the researched abuse, diversion and addiction-related surveillance system. J Pain. 2018;19(4):439–453. doi: 10.1016/j.jpain.2017.11.007.
    1. Frost DA, Soric MM, Kaiser R, Neugebauer RE. Efficacy of tramadol for pain management in patients receiving strong cytochrome P450 2D6 inhibitors. Pharmacotherapy. 2019;39(6):724–729. doi: 10.1002/phar.2269.
    1. Saarikoski T, Saari TI, Hagelberg NM, Backman JT, Neuvonen PJ, Scheinin M, et al. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Eur J Clin Pharmacol. 2015;71(3):321–327. doi: 10.1007/s00228-014-1799-2.
    1. Samer CF, Piguet V, Dayer P, Desmeules JA. Genetic polymorphism and drug interactions: their importance in the treatment of pain. Can J Anaesth. 2005;52(8):806–821. doi: 10.1007/BF03021775.
    1. Saarikoski T, Saari TI, Hagelberg NM, Neuvonen M, Neuvonen PJ, Scheinin M, et al. Rifampicin markedly decreases the exposure to oral and intravenous tramadol. Eur J Clin Pharmacol. 2013;69(6):1293–1301. doi: 10.1007/s00228-012-1460-x.
    1. Ikenberg R, Hertel N, Moore RA, Obradovic M, Baxter G, Conway P, et al. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J Med Econ. 2012;15(4):724–736. doi: 10.3111/13696998.2012.670174.
    1. Obradovic M, Ikenberg R, Hertel N, Antoñanzas F, Gálvez R, Liedgens H. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs. Clin Ther. 2012;34(4):926–943. doi: 10.1016/j.clinthera.2012.02.011.
    1. Neil N, Merchant S, Provenzano D, Ogden K, Mody SH. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States. J Med Econ. 2013;16(2):307–317. doi: 10.3111/13696998.2012.756401.
    1. Kwong WJ, Ozer-Stillman I, Miller JD, Haber NA, Russell MW, Kavanagh S. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. Clin Ther. 2010;32(10):1768–1781. doi: 10.1016/j.clinthera.2010.09.011.
    1. Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, et al. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain. Clin Ther. 2013;35(5):659–672. doi: 10.1016/j.clinthera.2013.03.016.
    1. Coluzzi F, Ruggeri M. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin. 2014;30(6):1139–1151. doi: 10.1185/03007995.2014.894501.
    1. Scarpignato C, Gatta L. Comparing tapentadol to oxycodone/naloxone combination: building castles in the air. Curr Med Res Opin. 2015;31(2):335–338. doi: 10.1185/03007995.2014.957823.
    1. Sullivan W, Hirst M, Beard S, Gladwell D, Fagnani F, López Bastida J, et al. Economic evaluation in chronic pain: a systematic review and de novo flexible economic model. Eur J Health Econ. 2016;17(6):755–770. doi: 10.1007/s10198-015-0720-y.
    1. Martindale W, Buckingham R. Martindale: the complete drug reference. 40. London: Pharmaceutical Press; 2020. p. 4912p.
    1. Palmaro A, Lapeyre-Mestre M. Comparative study of regulatory measures and analgesic consumption in Europe (2005–2015) Paris: French National Agency of Medicine (ANSM); 2017. p. p144.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner